Standard BioTools Inc. reported fourth quarter 2025 revenue of $23.8 million and full year 2025 revenue of $85.3 million. The company achieved over $40 million in cost savings and has approximately $550 million in cash & investments. The CEO, Michael Egholm, praised the team’s performance and efficiency gains, stating progress towards 2026 profitability targets. The company expects revenue in fiscal year 2026 to be in the range of $80 million to $85 million. Gross margins and non-GAAP gross margins were approximately 47.8% and 50.3% in the fourth quarter of 2025, respectively. Operating expenses were $36.0 million in the fourth quarter, with a net loss from continuing operations of $13.9 million. Adjusted EBITDA for the quarter was a loss of $15.8 million. For the full year 2025, revenue was $85.3 million, down 6% year-over-year, with a net loss of $58.8 million. Adjusted EBITDA for the year was a loss of $62.6 million. The company has NOL carryforwards of approximately $1 billion for US federal income tax purposes. Non-GAAP financial measures, including gross margin, operating expenses, and adjusted EBITDA, were presented to provide additional insight into the company’s performance, excluding non-cash expenses. Forward-looking statements were made regarding future financial performance, operational plans, and strategic acquisitions. Risk factors include potential integration challenges and market uncertainties. Standard BioTools Inc. is committed to setting new standards in the life science tools industry. For more information, visit standardbio.com.

Read more at GlobeNewswire: Standard BioTools Reports Fourth Quarter and Full Year 2025